Innovating in the field of Med Tech presents a host of unique challenges. Formulating new treatments is a long and capital-intensive process. The regulatory regime for medical devices is extremely stringent. And even if you get approval, you still need to convince doctors that your treatment is safe and effective. But success in Med Tech R & D doesn't just mean profits for the company and it's shareholders, it means new treatments that can dramatically improve or even save the lives of patients.

Jim Clemmer became the CEO of AngioDynamics in April of 2016, the company trades on the NASDAQ under the symbol ANGO. Prior to joining the company, Jim served as President of the multi-billion dollar medical supply segment at Covidien PLC where he directed the strategic and day-to-day operations for global business divisions that collectively manufactured 23 different product categories. In addition, he managed global manufacturing, research and development, operations, business development, and all other functions associated with the medical supplies business.

Jim joins us to discuss AngioDynamics' innovative products that are helping treat a range of conditions from pulmonary embolism to prostate cancer. He also explains how their continued commitment to innovation has set AngioDynamics up for future success.

Highlights:

The AngioDynamics Mission (4:03)
Managing the AngioDynamics Portfolio (5:04)
What sets AngioDynamics apart in the field (6:20)
Meeting real-world clinical needs (7:24)
AngioDynamics products (8:53)
AngioDynamics approach to R&D (12:45)
The impact on patients (15:36)
Navigating regulation in different markets (20:06)
The role of AI (21:35)
AngioDynamics' balance sheet (23:01)

Links:

AngioDynamics LinkedIn

AngioDynamics Website

ICR LinkedIn

ICR Twitter

ICR Website

Feedback:

If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, marion@lowerstreet.co.

260 - Untoxic (Part 5): Reflections on Power Dynamics and the Church